There are currently two FDA-approved BCMA-CARs for patients with heavily pretreated relapsed or refractory MM: idecabtagene/Abecma, which showed an overall response rate (ORR) of 73% with median progression free survival (PFS) of 12.1 months at target dose of 450 × 106, and ciltacabtagene/Carvykti (bi-epitope CAR containing 2 BCMA-targeting domains), which had an ORR of 97% and median PFS was not reached (Table 1) [128,129]. Here, TNFRSF17 is linked to Miyoshi myopathy.